Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis.
Direct oral anticoagulant
Extended oral anticoagulant therapy
Low-dose apixaban or rivaroxaban
Upper extremity deep venous thrombosis
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
01
06
2023
medline:
13
7
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Upper extremity deep vein thrombosis (UEDVT) may occur without inciting factor or may be secondary to malignancy, surgery, trauma, central venous catheter or related to thoracic outlet syndrome (TOS). International guidelines recommend anticoagulant treatment for at least three months, in particular the use of vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). No data on extended anticoagulant therapy and reduced dose of DOACs have been reported in patients affected by UEDVT with persistent thrombotic risk (active cancer, major congenital thrombophilia) or without affected vein recanalization. In our retrospective observational study, including 43 patients, we treated secondary UEDVT with DOACs. In the acute phase of thrombosis (median time of 4 months), we used therapeutic dose of DOACs; the 32 patients with permanent thrombotic risk factors or without recanalization of the UEDVT were shifted to low-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily). During therapy with full-dose DOACs, 1 patient presented recurrence of thrombosis; no thromboembolic events were observed during treatment with low-dose DOACs. During full-dose treatment, 3 patients presented minor hemorrhagic complications; no hemorrhagic events were observed during DOACs at low dose. We think our preliminary data could support the indication to extend the anticoagulation with dose reduction of DOACs in patients affected by UEDVT and no-transient thrombotic risk. These data should be confirmed in randomized controlled prospective study.
Identifiants
pubmed: 37341894
doi: 10.1007/s11239-023-02842-6
pii: 10.1007/s11239-023-02842-6
doi:
Substances chimiques
Rivaroxaban
9NDF7JZ4M3
apixaban
3Z9Y7UWC1J
Anticoagulants
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-326Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Isma N, Svensson PJ, Gottaster A, Lindblad B (2010) Upper extremity deep venous thrombosis in the population-based Malmö Thrombophilia Study (MATS): epidemiology, risk factors, recurrence risk, and mortality. Thromb Res 125(6):e335–e338
doi: 10.1016/j.thromres.2010.03.005
pubmed: 20406709
Joffe HV, Kucher N, Tapson VF, Goldhaber SZ (2004) Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 110:1605–1611
doi: 10.1161/01.CIR.0000142289.94369.D7
pubmed: 15353493
Muñoz FJ, Mismetti P, Poggio R et al (2008) Clinical outcome of patients with upperextremity deep vein thrombosis: results from the RIETE Registry. Chest 133:143–148
doi: 10.1378/chest.07-1432
pubmed: 17925416
Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo TC (2010) Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 21:779–787
doi: 10.1016/j.jvir.2010.02.021
pubmed: 20434365
Spencer FA, Emery C, Lessard D, Goldberg RJ (2007) Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 120:678–684
doi: 10.1016/j.amjmed.2006.06.046
pubmed: 17679126
pmcid: 3180814
Joffe HV, Kucher N, Tapson VF, Goldhaber SZ (2004) Deep vein thrombosis (DVT) FREE Steering Committee. Upper extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 110:1605–1611
doi: 10.1161/01.CIR.0000142289.94369.D7
pubmed: 15353493
Kucher N (2011) Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med. Mar 3;364(9):861-9. doi: https://doi.org/10.1056/NEJMcp1008740 . PMID: 21366477
Illig KA, Doyle AJ (2010) A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg. 2010 Jun;51(6):1538-47. doi: https://doi.org/10.1016/j.jvs.2009.12.022 . PMID: 20304578
Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Farjat AE, Zaghdoun A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Darius H, Kakkar AK (2019) Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thromb Haemost 119(8):1365–1372
doi: 10.1055/s-0039-1688828
pubmed: 31183844
Elman EE, Kahn SR (2006) The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 117:609–614
doi: 10.1016/j.thromres.2005.05.029
pubmed: 16002126
Bleker SM, van Es N, Kleinjan A et al (2016) Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis. J Thromb Haemost 14(5):973–981
doi: 10.1111/jth.13291
pubmed: 26866515
Flinterman LE, Van Der Meer FJM, Rosendaal FR, Doggen CJM (2008) Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 6(08):1262–1266
doi: 10.1111/j.1538-7836.2008.03017.x
pubmed: 18485082
Thiyagarajah K, Ellingwood L, Endres K et al (2019) Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: a systematic review and meta-analysis. Thromb Res 174:34–39
doi: 10.1016/j.thromres.2018.12.012
pubmed: 30553163
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723
doi: 10.1182/blood-2013-04-460121
pubmed: 23908465
Lyman GH, Carrier M, Ay C et al (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974
doi: 10.1182/bloodadvances.2020003442
pubmed: 33570602
pmcid: 7903232
Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Dec;160(6):e545-e608. doi: https://doi.org/10.1016/j.chest.2021.07.055
Moik F, Colling M, Mahé I, Jara-Palomares L, Pabinger I, Ay C (2022) Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost 20(3):619–634. https://doi.org/10.1111/jth.15599
doi: 10.1111/jth.15599
pubmed: 34816583
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694
doi: 10.1111/j.1538-7836.2005.01204.x
pubmed: 15842354
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed: american college of chest Physicians evidence based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S
doi: 10.1378/chest.11-2301
pubmed: 22315268
pmcid: 3278049
Valeriani E, Di Nisio M, Porceddu E, Agostini F, Pola R, Spoto S, Donadini MP, Ageno W, Porfidia A (2022) Anticoagulant treatment for upper extremity deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 20(3):661–670. https://doi.org/10.1111/jth.15614
doi: 10.1111/jth.15614
pubmed: 34846783
Davies GA, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M, Corpuz R, Kovacs MJ (2018) A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res 2018 Feb 162:88–92. https://doi.org/10.1016/j.thromres.2017.04.003
doi: 10.1016/j.thromres.2017.04.003
Montiel FS, Ghazvinian R, Gottsäter A, Elf J (2017) Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J. 2017 Oct 3;15:26. doi: https://doi.org/10.1186/s12959-017-0149-x . PMID: 29026346
Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M (2019) Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A Systematic Review and Meta-Analysis. J. Thromb. Haemost. JTH. 2019;17:645–656. doi: https://doi.org/10.1111/jth.14398
Larsen TL, Garresori H, Brekke J et al (2022) Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. J Thromb Haemost 20(5):1166–1181. https://doi.org/10.1111/jth.15666
doi: 10.1111/jth.15666
pubmed: 35114046
Vedovati MC, Tratar G, Mavri A, Mazzetti M, Salazar Rosa V, Pierpaoli L, Cotugno M, Agnelli G, Becattini C (2021) Upper extremities deep vein thrombosis treated with oral direct anticoagulants: a prospective cohort study. Int J Cardiol 2021 Sep 15:339:158–163. https://doi.org/10.1016/j.ijcard.2021.07.005
doi: 10.1016/j.ijcard.2021.07.005